Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation.

Published on Mar 1, 2020in Journal of Oncology Practice3.84
· DOI :10.1200/JOP.19.00567
Saad Ahmad Ali1
Estimated H-index: 1
(UIndy: University of Indianapolis),
Huseyin Emre Arman1
Estimated H-index: 1
(UIndy: University of Indianapolis)
+ 1 AuthorsRuemu Ejedafeta Birhiray1
Estimated H-index: 1
Sources
Abstract
References0
Newest
Cited By2
Newest
#1Eve LebasH-Index: 4
#2Nathalie MarchalH-Index: 1
Last. Arjen NikkelsH-Index: 29
view all 4 authors...
INTRODUCTION Locally advanced cutaneous squamous cell carcinoma (lacSCC) is rare. Approximately one-fourth of the cases are observed among immunocompromised patients, in particular in solid organ transplant recipients (OTRs). LacSCC has a very poor prognosis. Surgery with or without radiotherapy remains the golden standard of treatment for cSCC. However, in advanced cases, there is a medical need for alternative treatment options. Classic systemic treatments include chemotherapy and/or EGFR inhi...
Source
#1Luca Paoluzzi (Albert Einstein College of Medicine)H-Index: 16
#2Thomas J. Ow (Montefiore Medical Center)H-Index: 3
Immunotherapies directed at T-cell activation through antibodies targeting checkpoint proteins, such as programmed cell death 1 (PD1), are rapidly becoming the new standard of care in the treatment of several malignancies. Cemiplimab is a monoclonal antibody targeting PD1 that has recently emerged as a highly active treatment for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC). Patients who have received an organ transplant (OTRs) have been traditionally excluded from cl...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.